Cell Therapy Discovery Based on TCR-pMHC

Solutions

Online Inquiry

Intracellular tumor- or virus-associated antigens can be presented as peptides in cell surface MHCs, which interact with T-cell receptors (TCRs) on antigen-specific T cells to stimulate immune responses. TCR-peptide/MHC-based cell therapy is a promising strategy for the treatment of advanced cancer and viral infections. Creative BioMart offers cell therapy discovery services for cancer treatment, providing researchers with a rapid and effective platform to screen for TCR-pMHC interactions, offering valuable applications for personalized immunotherapy.

T Cell Therapy Based on TCR-pMHC

Fig.1 3D structure of the TCR-pMHC complex (Zoete V, et al., 2013)

Successful interaction between the TCR and the appropriate pMHC complex is a critical component of an effective antitumor immune response. pMHC can be recognized by autologous or allogeneic T cells containing the same MHC allele through TCR-pMHC interactions, and T cells then perform specific immunosurveillance functions to mediate apoptosis by secreting cytotoxic granules, cytokines, or perforins. Thus, we can screen and form functional TCRs based on pMHC to specifically redirect T cells to cancer antigens of interest to achieve an anti-cancer immune response.

To redirect T cells to tumor cells, T cells can be screened in vitro to generate tumor antigen-specific T cells or engineered to express cancer antigen-specific TCRs to generate functional T cells for therapy. In conclusion, we can adopt multiple immunotherapeutic strategies by targeting TCR-pMHC interactions.

Screening for TCR-pMHC Interactions

Transgenic T cells expressing antigen-specific TCRs could be used in a broader range of therapeutic applications, but the generation of high-affinity TCRs limits their application. We offer our customers an efficient and rapid technology platform for high-throughput screening of T cell antigen discovery based on TCR-pMHC Interactions.

Screening based on pMHC tetramers
The pMHC tetramer method uses pMHC multimers with DNA barcodes to detect TCR specificity. Our services include efficient production of stable and diverse pMHC multimers, high-throughput synthesis of peptides, and comprehensive exploration of antigenic targets to reduce errors.
Screening based on pMHC expressing cells
Using cell-based assays, we help screen for TCR-pMHC interactions by assessing the function of T cells after co-incubation with cells expressing pMHC, helping our clients to screen for a large number of epitopes at high throughput as well as reducing homologation errors.

Our Solutions Based on TCR-pMHC Strategy

We have been exploring tumor antigen-specific pMHC as a therapeutic diagnostic and target for cancer immunotherapy, providing TCR-based cell therapy development to further advance cancer immunotherapy. Therefore, we propose the following strategies to help pharmaceutical companies further develop cellular therapies for cancer.

Fig.2 Our solutions based on TCR-pMHC strategy.

Choose tumor-associated antigens correctly to prevent recognition of other homologous peptides.
Identify the ideal choice for TCR-pMHC interactions.
Modify T cells using tumor antigen-specific TCRs.
Generate and optimize therapeutic TCR-T cells.

T-cell therapies for cancer have great potential, and Creative BioMart offers research support for your early development results. If you would like more information and find a reliable partner for your project as well as high-quality research conditions, please do not hesitate to contact us.

Reference

Zoete V, et al. "Structure-based, rational design of T cell receptors." Frontiers in immunology (2013), 4:268.

For research use only. Not for clinical use.